The US Food and Drug Administration (FDA) has granted approval to Switzerland-based Roche for its Rozlytrek (entrectinib) intended for the treatment of adults with ROS1-positive and metastatic non-small cell lung cancer (NSCLC), it was reported on Friday.
The firm has also received accelerated approval for the product to treat adult and paediatric patients 12 years of age and older with solid tumours, which have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation.
Rozlytrek is an oral medicine and selective tyrosine kinase inhibitor developed to inhibit the kinase activity of the TRK A/B/C and ROS1 proteins. It holds capacity to inhibit ROS1 and NTRK kinase activity and is likely to result in the death of cancer cells with ROS1 or NTRK gene fusions. The product has received approvals based on data from the integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials, and data from the phase I/II STARTRK-NG study.
Roche has claimed that Rozlytrek shrank tumours in 78 percent of people with the disease and the duration of response (DoR) ranged from 1.8 to 36.8+ months in ROS1-positive and metastatic NSCLC.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review